BERLDRG

Beryl Drugs Ltd.

BSE: 524606

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

25.85-0.5 (-1.75%)

12 Oct, 1:59 PM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

Score not available

Value Score

Score not available

Price Momentum Score

Score not available

QVM Score

Score not available

Key Metrics

Market Cap

13.39

P/E (TTM)

21.44

P/B

1.35

P/S (TTM)

0.63

EV/EBITDA

8.52

CAPE (5Y)

35.60

ROE (TTM)

4.38

ROCE (TTM)

3.41

ROA (TTM)

2.75

Avg 3Y ROE

6.57

Earnings 3Y CAGR

-16.44

Sales 3Y CAGR

-10.82

Sales 5Y CAGR

5.96

Debt/Equity

0.25

Consensus TP

Strong Buy %

Promoter Holding

27.82

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Beryl Drugs Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Stock is reasonably valued and PE TTM is at a discount to industry median

PE TTM of 21.44 indicates that the stock is reasonably valued on a standalone basis. Discount to industry median P/E is decent at -31.89%

What is P/E Ratio?

Median: 31.48

Value 21.44

-0.8734.68

Strong EPS growth and above median growth of industry

The company delivered strong EPS growth of 172.26% for 12-month ended 30 Jun 2026 and the growth was 164.81 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.25 as on 30 Jun 2026 and Debt to Equity decreased marginally by 0.18 in the last 1 year

What is Debt to Equity?

Negative

Low and declining ROE

The company reported low ROE of 4.38% for 12-month ended 30 Jun 2026 and ROE declined by -189 bps from 1 year ago

What is ROE (FY)?

Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of 8.28% for 12-month ended 30 Jun 2026 and the growth was 2.4 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 10.68

Value 8.28

-99.6111701.8

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Low operating margin but improving trend

The company reported low operating margin of 1.76% for 12-month ended 30 Jun 2026 but operating margin improved by 455 bps from 1 year ago

What is Operating profit margin?

Financial Snapshot

See detailed analysis

Multi-year trends for Beryl Drugs Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Beryl Drugs Ltd. Shareholding Pattern

Quarterly breakdown of Beryl Drugs Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	24.92	24.92	24.92	24.92	24.92	24.92	24.92	24.92	24.92	24.92	24.92	24.92	26.38	26.38	26.38	26.38	26.38	26.38	26.38	26.38	26.38	26.38	26.38	26.38	27.48	27.82
Indian Promoter	24.92	24.92	24.92	24.92	24.92	24.92	24.92	24.92	24.92	24.92	24.92	24.92	26.38	26.38	26.38	26.38	26.38	26.38	26.38	26.38	26.38	26.38	26.38	26.38	27.48	27.82
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00
Mutual Funds / UTI	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Non-Institution	75.08	75.08	75.08	75.08	75.08	75.08	75.08	75.08	75.08	75.08	75.08	75.08	73.62	73.62	73.62	73.62	73.62	73.62	73.62	73.62	73.62	73.62	73.62	73.62	72.52	72.18
Bodies Corporate	4.41	6.58	4.23	3.27	3.40	3.40	3.25	3.25	3.25	3.25	2.58	2.42	2.42	2.41	2.62	2.79	4.46	2.81	3.04	2.85	2.69	2.46	2.61	2.61	2.92	2.69
Others (incl. Retail) No. of shareholders	70.67 6,425	68.50 6,460	70.85 6,451	71.81 6,444	71.68 6,412	71.68 6,578	71.83 6,823	71.83 6,930	71.83 6,948	71.83 6,934	72.50 6,934	72.66 6,896	71.20 6,852	71.21 6,758	71.00 6,761	70.83 6,808	69.16 7,212	70.81 7,282	70.58 7,319	70.77 7,385	70.93 7,387	71.16 7,373	71.01 7,402	71.01 7,365	69.60 7,305	69.49 7,265

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Beryl Drugs Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
SUDHIR SETHI Promoter and Director	August-2026	Market Purchase (Acquisition) 18th Aug 2026	10.08 %	₹ 23.00	3.00 k	₹ 69.00 k
SUDHIR SETHI Promoter & Director	June-2026	Market Purchase (Acquisition) 9th Jun 2026	9.75 %	₹ 24.00	4.68 k	₹ 1.12 lac
SUDHIR SETHI Promoter & Director	June-2026	Market Purchase (Acquisition) 7th Jun 2026	9.72 %	₹ 21.92	1.99 k	₹ 43.66 k
SUDHIR SETHI Promoter & Director	March-2026	Market Purchase (Acquisition) 25th Mar 2026	9.58 %	₹ 20.99	7.50 k	₹ 1.57 lac
SUDHIR SETHI Promoter & Director	March-2026	Market Purchase (Acquisition) 24th Mar 2026	9.44 %	₹ 20.75	7.50 k	₹ 1.56 lac
SUDHIR SETHI Promoter & Director	March-2026	Market Purchase (Acquisition) 21st Mar 2026	9.42 %	₹ 20.80	800.00	₹ 16.64 k
SUDHIR SETHI Promoter & Director	March-2026	Market Purchase (Acquisition) 17th Mar 2026	9.33 %	₹ 20.20	5.00 k	₹ 1.01 lac
SUDHIR SETHI Promoter & Director	March-2026	Market Purchase (Acquisition) 14th Mar 2026	9.27 %	₹ 20.23	3.04 k	₹ 61.50 k
SUDHIR SETHI Promoter & Director	March-2026	Market Purchase (Acquisition) 13th Mar 2026	8.98 %	₹ 20.48	15.00 k	₹ 3.07 lac
SUDHIR SETHI Promoter & Director	March-2026	Market Purchase (Acquisition) 12th Mar 2026	8.88 %	₹ 20.88	4.85 k	₹ 1.01 lac

No corporate action data available.

Company Profile

Overview of Beryl Drugs Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Beryl Drugs Limited is an India-based pharmaceutical manufacturing company which is principally engaged in the manufacturing of bulk drugs. The Company operates in Pharmaceutical Industry segment. In response to product requirements, it provides a variety of manufacturing options, such as small volu...

Key personnel

Mr. Ashish Baraskar

Chief Financial Officer

Kamlesh Gupta

Compliance Officer, Company Secretary

Mr. Sudhir SethiD

Non-Executive Chairman of the Board

Mr. Sanjay SethiD

Managing Director, Executive Director

Mr. Shailendra PathakD

Whole Time Director

Mr. Abhinav NaikD

Independent Non-Executive Director

Mrs. Shreya SarafD

Independent Non-Executive Director

Neha SardaD

Non-Executive Independent Director

Incorporated on

24 Aug 1993

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

IPO date

16 Jun 1994

Free Float

30,18,767

Website

https://www.beryldrugs.com/

Phone no.

+917312517677

Address

133 KANCHAN BAGH, , 452001, India

Frequently Asked Questions

What is the current share price of Beryl Drugs Ltd.?

The current share price of Beryl Drugs Ltd. is ₹ 25.85 as of 12 Oct 2026.

What is the market capitalisation of Beryl Drugs Ltd.?

The market capitalisation of Beryl Drugs Ltd. stands at ₹ 13.39 Cr.

What is the PE ratio of Beryl Drugs Ltd.?

The Price-to-Earnings (PE) ratio of Beryl Drugs Ltd. is 21.44 as of the latest trailing twelve months data.

What is the ROE and ROCE of Beryl Drugs Ltd.?

Beryl Drugs Ltd. has a Return on Equity (ROE) of 4.38% and a Return on Capital Employed (ROCE) of 3.41% as per the latest financial reports.

What is the 52-week high and low of Beryl Drugs Ltd.?

The 52-week high of Beryl Drugs Ltd. is - and the 52-week low is -.

What is the dividend yield of Beryl Drugs Ltd.?

The dividend yield of Beryl Drugs Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Beryl Drugs Ltd.?

Foreign Institutional Investors (FII) hold 0.00%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 69.49% of Beryl Drugs Ltd. shares.

What sector does Beryl Drugs Ltd. belong to?

Beryl Drugs Ltd. operates in the Healthcare sector.

What is the beta of Beryl Drugs Ltd.?

The beta of Beryl Drugs Ltd. is 0.94, indicating its price volatility relative to the broader market. Over the past 1 year, Beryl Drugs Ltd. has delivered an absolute return of 9.14%.

What is the RSI of Beryl Drugs Ltd.?

The 14-day Relative Strength Index (RSI) of Beryl Drugs Ltd. is 60.93, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Beryl Drugs Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Beryl Drugs Ltd. Shareholding Pattern

Bulk, Block and Insider Trades

Company Profile

Frequently Asked Questions

Stock Analysis

Company Profile